Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Sotatercept Dosing Strategies in Pulmonary Arterial Hypertension
2024-512278-92-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 22
01
Overview
Phase 2, randomised, single-blind trial of sotatercept in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Merck & Co. Primary endpoints: Steady-state average serum concentrations of sotatercept (Cavg), Number of participants who experience one or more adverse events (AEs) and 1 more. Started Nov 2024; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2024-512278-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512278-92-00.